15 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 30663560 | Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. | 2020 | 1 |
2 | 30554037 | Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells. | 2019 Feb | 1 |
3 | 27030119 | [Incretin therapies and multifactorial clinical approach to cardiometabolic patients]. | 2016 Mar | 1 |
4 | 26788106 | Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors. | 2015 | 2 |
5 | 22382611 | Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide. | 2012 Mar | 2 |
6 | 21871831 | Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. | 2011 Dec | 2 |
7 | 20380648 | Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. | 2010 Apr | 1 |
8 | 19182763 | Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. | 2009 Jan | 1 |
9 | 19952298 | Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. | 2009 Dec | 1 |
10 | 18020966 | The entero-insular axis: implications for human metabolism. | 2008 | 1 |
11 | 18201204 | Effects of exendin-4 on islets from type 2 diabetes patients. | 2008 Jun | 1 |
12 | 18402245 | Glucagon-like peptide 1 based therapy for type 2 diabetes. | 2008 Feb | 1 |
13 | 18630617 | [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus]. | 2008 Apr | 1 |
14 | 27056542 | Incretin-based Therapies for Type 2 Diabetes. | 2008 | 1 |
15 | 17263764 | Incretins and other peptides in the treatment of diabetes. | 2007 Mar | 2 |